Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

EcoR1 Capital

Investor type Private Equity Firm
Founders Oleg Nodelman

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 92
Average round size
info
The average size of a deal this fund participated in
$93M
Portfolio companies 73
Rounds per year 9.20
Lead investments 6
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.21
Exits 56
Key employees 2
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Therapeutics
  • Health Care
  • Medical
  • Pharmaceutical
Summary

EcoR1 Capital appeared to be the VC, which was created in 2012. The fund was located in North America if to be more exact in United States. The main office of represented VC is situated in the San Francisco.

We also calculated 2 valuable employees in our database.

The usual cause for the fund is to invest in rounds with 8-9 partakers. Despite the EcoR1 Capital, startups are often financed by ARCH Venture Partners, Third Rock Ventures, The Column Group. The meaningful sponsors for the fund in investment in the same round are Fidelity Management and Research Company, Cormorant Asset Management, Samsara BioCapital. In the next rounds fund is usually obtained by Polaris Partners, Fidelity Management and Research Company, Cormorant Asset Management.

Among the most popular portfolio startups of the fund, we may highlight Clementia Pharmaceuticals, Relay Therapeutics, Codiak Biosciences. Among the most popular fund investment industries, there are Genetics, Medical Device. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little.

The increased amount of exits for fund were in 2018. The fund is generally included in 2-6 deals every year. Speaking about the real fund results, this VC is 15 percentage points less often commits exit comparing to other organizations. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. Deals in the range of 50 - 100 millions dollars are the general things for fund. This EcoR1 Capital works on 22 percentage points more the average amount of lead investments comparing to the other organizations.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of EcoR1 Capital:
Typical Co-investors
EcoR1 Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after EcoR1 Capital:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

BioAtla

Biotechnology
Health Care
Medical
$65M04 Nov 2022 San Diego, California, United States

Abeona Therapeutics

Biotechnology
Genetics
Health Care
Medical Device
$35M03 Nov 2022 New York, New York, United States

immatics biotechnologies

Biotechnology
Medical
Therapeutics
$110M10 Oct 2022 Germany, Baden-Württemberg, Germany

Ventyx Biosciences

Biopharma
Biotechnology
$176M19 Sep 2022 Encinitas, California, United States

SpringWorks Therapeutics

Biopharma
Biotechnology
Therapeutics
$225M07 Sep 2022 Stamford, Connecticut, United States

Kymera Therapeutics

Biotechnology
Health Care
Medical
Therapeutics
$150M19 Aug 2022 Cambridge, Massachusetts, United States

AlloVir

Biotechnology
Clinical Trials
Pharmaceutical
$126M27 Jul 2022 Houston, Texas, United States

Gossamer Bio

Biotechnology
Health Care
Therapeutics
$120M13 Jul 2022 San Diego, California, United States

Tempest Therapeutics

Biotechnology
Health Care
Therapeutics
$15M27 Apr 2022 San Francisco, California, United States
News
ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million

– ReCode Therapeutics announced the closing of an $80m Series B financing round co-led by Pfizer Ventures and EcoR1 Capital.
– The round was led by Pfizer Ventures and EcoR1 Capital.
– New investors include Sanofi Ventures, funds managed by Tekla Capital Management, Superstring Capital and NS Investment.
– Existing investors who participated included OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, and Osage University Partners.

Ajax Therapeutics Raises $40 Million Financing To Develop Novel Small Molecules Targeting Cytokine Signaling Pathways for Hematologic Malignancies

– Ajax Therapeutics, Inc. announced the completion of a $40m financing.
– The round was led by EcoR1 Capital LLC with participation from additional new investor, Boxer Capital, as well as co-founding investors Inning One Ventures and Schrödinger, Inc.
– Existing research collaboration partners, Memorial Sloan Kettering Cancer Center (MSK) and NYU Langone Health, also participated in the financing.
– Concurrent with the financing, Scott Platshon, Partner of EcoR1 Capital, will join the Ajax Board of Directors.
– Proceeds from the financing will support the advancement of Ajax’ lead drug development programs targeting hematologic malignancies.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent EcoR1 Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: